Eli Lilly and Co. reported strong second-quarter results, beating Wall Street estimates and prompting the company to raise its full-year revenue forecast by $3 billion.

Eli Lilly (LLY) shares surged higher in premarket trading Thursday after the drugmaker's second-quarter earnings came in well above analysts' estimates and it raised its full-year revenue and profi...

Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%.

MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs proudly unveils LLYX, the world's first single-stock leveraged ETF for Eli Lilly. LLYX offers retail investors 2X daily long leveraged exposur...

A rival pharmaceutical company released promising clinical trial results from a weight-loss treatment. Eli Lilly is one of two companies dominating the obesity drug market right now.

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

As Eli Lilly's weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk's Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my pati...

Eli Lilly shares have soared more than 230% over the past three years. The company has generated major growth thanks to its weight loss drugs.

My initial bearish thesis about Eli Lilly stock did not age well, as the stock has performed well since February despite being substantially overvalued. However, the market appears to be comfortabl...

A clinical trial starring patients with both obesity and heart failure says treatment with tirzepatide provides a big risk reduction. Tirzepatide is the active ingredient in both Mounjaro, a diabet...

With a rich history dating back to the 19th century, Eli Lilly (LLY) has faced struggles and successes. But a booming market cap has quickly turned it into the biggest pharmaceutical brand in the w...

A recent study compared the effectiveness of tirzepatide against semaglutide. Tirzepatide has been more effective in helping people lose weight in trials, and the study corroborated that.

Eli Lilly (LLY) reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.

Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization , oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepati...

A Japanese health ministry panel on Thursday recommended approval for Eli Lilly's dementia treatment donanemab.